aleenadaniel

898

The uncomplicated urinary tract infection treatment market is expected to rise from its present value of US$ 5.96 billion in 2022 to US$ 17 billion by 2023, with a compound annual growth rate (CAGR) of 10% from 2023 to 2033. The high frequency of UTIs, the rise in antibiotic resistance, and growing public awareness of the importance of appropriate UTI management are all contributing to the growth of the market for simple urinary tract infection treatment. The market for treating simple urinary tract infections grew at a 5.7% compound annual growth rate (CAGR) between 2018 and 2022.

One of the key drivers of the market is the increasing awareness of UTIs. With the growing availability of information online and through social media, more and more people are becoming aware of the symptoms of UTIs and the importance of seeking prompt treatment. This is leading to higher demand for antibiotics and other treatments, driving growth in the market.

Seize Excellence Today: Claim Your Sample for Unmatched Efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16923

Another factor driving the market is the growing geriatric population. As people age, their risk of developing UTIs increases, and with the world’s population aging rapidly, the demand for UTI treatments is also increasing. According to the United Nations, the number of people aged 65 and over is expected to triple by 2050, reaching nearly 1.5 billion.

Finally, the rising incidence of UTIs is also contributing to the growth of the market. Factors such as the growing prevalence of diabetes, changes in sexual behavior, and the increasing use of catheters and other medical devices are all leading to higher rates of UTIs. This is creating a growing demand for effective treatments that can quickly and safely clear up UTIs.

Key Takeaways:

The global Uncomplicated urinary tract infection treatment market is expected to grow with a 10% CAGR during 2023 to 2033. Retail pharmacies are expected to hold 47% of the market share in 2023 for Uncomplicated urinary tract infection treatment market. North America is expected to possess 48% market share for Uncomplicated urinary tract infection treatment market in 2023. Europe uncomplicated urinary tract infection treatment market size is expected to possess 40% market share in 2023. Retail Pharmacies Expected to Procure 47% Market Share for Uncomplicated Urinary Tract Infection Treatment Market: FMI Study

Key players are investing heavily in research and development to bring new and improved treatments to market, and are also working to expand their distribution networks to reach more patients.” states an FMI analyst

Competitive Landscape :

Key players in the uncomplicated urinary tract infection treatment market are GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, Pfizer, Allergan Plc, Bristol-Myers Squibb, Merck Co., Inc., Cipla Inc.

GSK has developed a drug called Avycaz, which is a combination of ceftazidime and avibactam, used for the treatment of complicated UTIs. Avycaz is effective against a wide range of gram-negative bacteria, including some that are resistant to other antibiotics. Iterum Therapeutics is a biopharmaceutical company that is focusing on developing novel antibiotics to treat infections caused by multi-drug resistant pathogens, including those that cause Uncomplicated Urinary Tract Infections (UTIs).

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Uncomplicated urinary tract infection treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights based on Drug Class (Gepotidacin, Probenecid, Sulfonamide, Tetracycline, Nitrofuran) Distribution Channel (Hospital Pharmacies, Gynaecology and Urology Clinics, Retail Pharmacies, Online Drug Stores) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East Africa)

Key Segments Profiled in the Uncomplicated Urinary Tract Infection Treatment Industry Survey

Drug Class:

Gepotidacin Probenecid Sulfonamide Tetracycline Nitrofuran

Distribution Channel:

Hospital Pharmacies Gynaecology and Urology Clinics Retail Pharmacies Online Drug Stores

The stereotactic surgery devices market for instruments used in stereotactic surgery is expected to grow at a 4.1% CAGR, from US$ 26.34 billion in 2023 to US$ 39.36 billion in 2033.

Rising demand for minimally invasive procedures, an increase in the occurrence of cancer, and technological advancements in stereotactic surgery equipment are the main drivers driving demand for these devices.

During the first half of the covid-19 pandemic, countries such as India and Malaysia saw a substantial drop in medical tourism. This is due to travel restrictions established by many countries in order to prevent the virus from spreading. Nonetheless, the government’s numerous tactics for controlling the crisis, as well as mass vaccination efforts, assisted the economy in opening up and operating at full capacity. As a result, it aided the market’s recovery at a rapid speed in the second half of the epidemic.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16922

With governments and various healthcare professionals focused on research and development and investments in the healthcare sector, the next developments might drive the expansion of the stereotactic surgery instruments industry. Furthermore, the increasing use of these devices in patients with arteriovenous malformations, epilepsy, and Parkinson’s disease is likely to provide a substantial boost to the market in the future years. The rising prevalence of these medical disorders is also projected to accelerate the adoption of stereotactic surgery instruments.

One of the most effective cancer treatments is radiosurgery. Stereotactic radiosurgery allows for the precise treatment of malignancies with high-dose radiation. Technical improvements in stereotactic radiosurgery aid in boosting treatment precision. Moreover, stereotactic radiosurgery aids in concentrating radiation dose on tumor cell lining, reducing the influence of radiation on adjacent healthy tissues.

Stereotactic radiosurgery and accompanying equipment are incorporating a variety of technologies. Radiosurgery therapies based on Varian technology help physicians treat many forms of cancer. Varian Medical Systems provide the Edge radiosurgery system, which is based on Varian technology and includes other technological components. Clinics, for example, can employ this modern equipment to perform streamlined stereotactic radiosurgery with speed and precision.

Despite the numerous benefits of stereotactic surgery, the expensive cost of stereotactic instruments is projected to stymie market expansion. Stereotactic radiosurgery can be delivered using ordinary Linear Accelerators (LINACs) or systems such as Gamma Knife. Unfortunately, many nations lack the financing and money to maintain such expensive radiation systems, which may have a negative impact on market growth.

Key Points:

The market is expected to surpass US$ 39.36 billion by 2033. Rising surgical procedures, growing cancer prevalence, and increased government awareness campaigns are key factors boosting market expansion. Stereotactic surgery devices market is expected to hold a CAGR of 4.1% during the forecast period 2023 to 2033. North America dominated the stereotactic surgery devices market.

Key Developments:

October 2021 – Ion Beam Applications SA announced the launch of the world’s first online proton therapy platform. June 2021 – Navi Netics Inc. received premarket product approval from the US Food and Drug Administration for their NaviNeticsD1 Stereotactic System. June 2021 – Elekta AB gained product approval from the US FDA for their linear accelerator-based Elekta harmony radiation therapy system. May 2022 – Elekta AB introduced the Elekta Spirit, a Next-generation Gamma Knife that will offer individualized radiosurgery with sub-milli-meter accuracy and treatment planning in less than 60 seconds.

Key Companies:

Koninklijke Philips N.V. Hitachi Medical Systems Huiheng Group Siemens Ag Elekta AB Varian Medical Systems IBA Accuray Incorporated

Key Segmentation:

Stereotactic Surgery Devices Market by Product:

Stereotactic surgery devices market for Gamma Knife Stereotactic surgery devices market for LINAC Stereotactic surgery devices market for PBRT Stereotactic surgery devices market for Cyber Knife

Stereotactic Surgery Devices Market by Application:

Stereotactic surgery devices market for Liver Stereotactic surgery devices market for Breast Stereotactic surgery devices market for Prostate Stereotactic surgery devices market for Lung Stereotactic surgery devices market for Colon

Stereotactic Surgery Devices Market by Region:

Stereotactic Surgery Devices in North America Market Stereotactic Surgery Devices in Europe Market Stereotactic Surgery Devices in Asia Pacific Market Stereotactic Surgery Devices in Latin America Market Stereotactic Surgery Devices in the Middle East Africa Market

The global hand-held X-rays market is anticipated to expand at a compound annual growth rate (CAGR) of 10.9% between 2023 and 2033, per the latest market data from FMI. The market is expected to be valued US$ 805.69 million in 2023. It is projected that the worth will amount to US$ 2,267.17 million by 2033.
In a variety of healthcare settings, such as clinics, emergency rooms, dentistry offices, veterinary clinics, and hospitals, handheld X-ray machines are frequently utilised. They are used for a number of diagnostic tasks, including bedside imaging, dental condition assessment, and fracture detection.

The Hand-held X-rays Market is experiencing rapid growth and innovation, revolutionizing the field of medical imaging. These portable X-ray devices offer flexibility and convenience, allowing healthcare professionals to perform on-the-spot diagnostic imaging without the need for patients to be transported to radiology departments. They are particularly valuable in emergency situations, field hospitals, and remote healthcare settings where immediate access to diagnostic information is critical for timely patient care. The market’s growth is also attributed to technological advancements, such as digital radiography and wireless connectivity, which enhance image quality, reduce radiation exposure, and streamline data management.

Seize Excellence Today: Claim Your Sample for Unmatched Efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16909

Furthermore, the Hand-held X-rays Market is expanding beyond traditional healthcare settings. These portable devices are finding applications in veterinary medicine, dental clinics, and industrial inspections, where their compact design and mobility are highly advantageous. With the growing demand for point-of-care diagnostics and the continuous evolution of handheld X-ray technology, the market is poised to see sustained growth in the coming years. As the global healthcare landscape continues to evolve, hand-held X-ray devices are becoming an indispensable tool for healthcare providers and professionals in various fields, enabling them to deliver faster, more efficient, and more accurate diagnostics.

Crucial Growth Factors:
The hand-held X-ray market is expected to experience growth due to several factors:

• Demographic shifts and global aging trends have led to an increase in the elderly population worldwide

• Orthopedic conditions, cancers, accidents, and other ailments are becoming more prevalent, contributing to the rising demand for medical devices

• Compared to traditional devices, modern medical devices offer greater convenience and comfort to patients, enhancing their overall experience and promoting better compliance with treatment regimes.
The hand-held X-rays market is witnessing a surge in demand due to the devices’ ability to provide high patient output rates and fast imaging. Moreover, the device produces good-quality images and low radiation risks. Also, the market is expected to expand rapidly due to advancements in the field of osteopathy and an increase in sports-related injuries.

Additionally, the government’s increased focus on providing high-quality diagnostic imaging at a lower cost is driving the demand for hand-held X-ray units. Investments in research and development play a crucial role in the growth of the hand-held X-rays market. As leading market players focus on upgrading their devices and developing new detection techniques. These advancements not only increase the revenues of key players but also drive the overall growth rate of the hand-held X-rays market.

Restraining Factor:
Hand-held X-ray equipment can capture private patient information, making them vulnerable to hacker attacks and data breaches. This crucial aspect can limit the market to some extent.

Key Takeaways:
• In 2023, North America is anticipated to hold a notable market share of 34.3% in the hand-held X-rays market. This dominance can be attributed to the region’s significant presence of service providers. Besides, several surgical procedures are being carried out by key companies in the region.

• The ADB forecasts that by 2050, one in four individuals in Asia Pacific is expected to be over 60 years old. Besides, the population of older people in the region is projected to reach close to 1.3 billion.
• The hospital segment is projected to hold a substantial market share of 47.2% in 2023. It is primarily attributed to the growth of the hospital industry, a rise in orthopedic surgeries, and an expanding patient population.

• The orthopedic segment is anticipated to experience a CAGR of 12.5%, fueled by many orthopedic surgeries.

• The hand-held X-rays market is poised to witness remarkable growth, with the dental segment projected to dominate and likely to capture a market share of 93.5% in 2023. The growth of this segment is driven by an increase in individuals with dental issues.

Competitive Background:

The key players operating in the hand-held X-rays market are investing in mergers and acquisitions to gain a significant market share. The manufacturers are also investing in research and development, and are introducing innovative methods to boost production capacity. Product development and market expansion are significant aspects of the hand-held X-rays market. As a result, market participants are likely to have a better overall revenue share in the global market.

Key Players:
• Dental Imaging Technologies Corporation
• REMEDI Co., Ltd
• Genoray
• OXOS Medical
• MaxRayCocoon.com
• Digital Doc LLC.
• EVIDENT
• Carestream Dental LLC

Key Segments:
Hand-held X-rays as an Application:
• Dental
• Orthopedic
• Others

Hand-held X-rays for End User:
• Hand-held X-rays for Hospitals
• Hand-held X-rays for Outpatient Facilities
• Hand-held X-rays for Research & Manufacturing

Future Market Insights projects a 10.3% compound annual growth rate (CAGR) for the renal insufficiency treatment market from 2023 to 2033. The worldwide market for treatments for renal insufficiency is projected to reach a market worth of US$ 35.58 billion by 2033. The rising incidence of kidney illnesses, an aging population, and technical developments in the management of renal insufficiency are all factors contributing to the market’s expansion.

According to the Centres for Disease Control and Prevention (CDC), more than 37 Million people in the United States have kidney disease and over 700,000 Americans are living with kidney failure, also known as end-stage renal disease (ESRD). In addition, kidney disease is a leading cause of death worldwide, with over 1.2 Million deaths attributed to the disease in 2020 alone.

The increasing prevalence of kidney diseases is expected to drive the growth of the renal insufficiency treatment market, which includes a range of treatments for kidney failure and other renal disorders. These treatments include hemodialysis, peritoneal dialysis, kidney transplant, and medication.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16898

Technological advancements in renal insufficiency treatment are also expected to drive the growth of the market. For example, the development of more advanced hemodialysis machines and catheters has made the procedure safer and more comfortable for patients, while the development of automated peritoneal dialysis machines has made peritoneal dialysis more accessible and convenient for patients.

Key Takeaways:

The global renal insufficiency treatment market is expected to grow with a 10.3% CAGR from 2023 to 2033.
By end user, dialysis centres are expected to hold 45% of the market share in 2023 for Renal insufficiency treatment market.
North America is expected to possess 48% market share for Renal insufficiency treatment market in 2023.
Europe Renal insufficiency treatment market size is expected to possess 41% market share in 2023.
“An increasing prevalence of kidney diseases, a growing aging population, and technological advancements in renal insufficiency treatment,” states an analysts at FMI

Competitive Landscape:

Key players in the renal insufficiency treatment are Nipro Corp., Fresenius Medical Care AG & Co. KGaA, Baxter International, Inc., Medtronic Plc, Braun Melsungen AG, Asahi Kasei Medical Co., Ltd., Cantel Medical, Nikkiso Co., Ltd., JMS Co. Ltd., AstraZeneca

Nipro Corporation produces a range of peritoneal dialysis products, including CAPD sets and cycler machines for automated peritoneal dialysis.
Fresenius Medical Care produces a range of dialysis machines, dialyzers, bloodlines, and other equipment and supplies for use in hemodialysis and peritoneal dialysis treatment.
More Valuable Insights:

Future Market Insights, in its new offering, presents an unbiased analysis of the global Renal insufficiency treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Treatment Type (Dialysis, Medication, Kidney Transplantation) End User (Dialysis Centres, Hospital & Clinics, Research & Academic Institutes) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa)

Key Segments:

By Treatment Type:

Dialysis
Medication
Kidney Transplantation
By End User:

Dialysis Centres
Hospital & Clinics
Research & Academic Institutes
By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

By 2023, analysts forecast that the cell dissociation market will be worth US$ 352.91 million and grow at a CAGR of 13.55% from 2023 to 2033. The cell dissociation sector is anticipated to bring in US$1,257.59 million by 2033.

The Cell Dissociation Market plays a crucial role in various fields of life sciences and biotechnology by providing tools and reagents for the efficient separation of cells from tissues and cell aggregates. These dissociation methods are essential for a wide range of applications, including cell culture, cell analysis, and cell-based assays.

Cell dissociation enzymes, mechanical dissociation devices, and chemical dissociation reagents are some of the key products in this market. Researchers and scientists rely on these tools to obtain single-cell suspensions for downstream applications, such as flow cytometry, cell sorting, and gene expression analysis.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16892

The market has seen significant growth in recent years due to the increasing demand for cell-based research and therapies. With advancements in regenerative medicine and the development of cell-based therapies, the Cell Dissociation Market is expected to continue expanding. Moreover, the ongoing research into cancer biology, stem cell biology, and immunology is driving the need for precise and gentle cell dissociation techniques, further fueling the market’s growth. As the life sciences field continues to evolve, the Cell Dissociation Market is well-positioned to provide critical tools for researchers and clinicians working on groundbreaking discoveries and therapies.

Synopsis of the Global Cell Dissociation Market:

The cell dissociation industry is booming as a result of accelerated research and development spending by biopharmaceutical companies. Cell dissociation is an essential task in biopharmaceutical research as it’s directly involved in medicine creation and pathophysiology explanation.

The biopharmaceutical sector is a dynamically developing segment of the pharmaceutical industry, with significant consequences for healthcare. Opportunities in biopharmaceuticals have emerged in the previous decade as a result of their excellent efficacy and safety.

Many benefits of using biopharmaceuticals, including reduced side effects, and the possibility to treat the underlying cause of an illness have increased demand for medicines. There is growth in public and private investment due to the advent of products with better tissue dissociation enzymes. As a result, the cell dissociation industry flourished.

There are limited cell dissociation industry growth restrictions, despite the several significant market determinants. The cell dissociation industry growth may be constrained by soft tissue operations’ high cost.

Another factor that could slow the cell dissociation market growth is the preference for enzyme-free over enzymatic dissociation products.

Product Insight:

The cell dissociation market is categorized into enzymatic dissociation products, instruments & accessories, and non-enzymatic dissociation products. A range of enzymes is utilized in research for various purposes. Enzymatic dissociation products hold the lion’s market share.

Trypsin, collagenase, elastase, and hyaluronidase are often used in enzymatic dissociation products. Enzymes are deployed in stem cell research and cell biology studies for cell and tissue dissociation, and single-cell harvesting. The use of enzymes for cell dissociation is fairly prevalent.

Regional Viewpoint:

In 2023, North America is going to have a high-income share. Rising cancer and chronic illness, strong trend of research and development investments, acquisitions, and collaboration by companies are the factors driving the market growth in North America.

The rising frequencies of chronic diseases in developing countries and increased government initiatives strengthen market growth in the Asia Pacific. The emerging use of cell-based assays and the availability of low-cost cell lysis and dissociation solutions may spur market expansion.

Throughout the forecast period, Europe’s cell dissociation industry may account for the second leading revenue share. Europe’s established biotech and pharmaceutical enterprises may contribute to cell dissociation market growth.

Key Takeaways:

The enzymatic dissociation category is likely to lead the market, accounting for almost 47.90% of sales in 2023.
From 2023 to 2033, the non-enzymatic segment in the cell dissociation industry is likely to expand at a significant CAGR.
In 2023, the tissue dissociation type segment is dominant, accounting for 56.55% of the cell dissociation industry.
Throughout the predicted period, the cell detachment type segment may blossom at a swift CAGR.
In 2023, the pharmaceutical and biotechnology firms’ end-user segment is likely to dominate, accounting for 71.60% of the cell dissociation industry.
North America is likely to lead the cell dissociation industry, accounting for 37.20% of the market in 2023.
During the predicted period, Asia Pacific to exhibit a significant CAGR.
Economic Environment:

Leading cell dissociation manufacturers are investing in toxicity and efficacy investigations involving cell dissociation enzymes. This aspect is predicted to power substantial growth in the cell dissociation market during the forecast years.

To increase the industry footprint, cell dissociation manufacturers implement a variety of initiatives such as partnerships, mergers, acquisitions, and expansions.

Strategic Progressions for Cell Dissociation:

Acquisitions:

December 8, 2021
PPD, Inc., a prominent provider of clinical research services, was acquired by Thermo Fisher Scientific Inc. The acquisition was valued at around US$ 17.4 billion and designed to boost Thermo Fisher Scientific’s position in the life sciences sector.

April 9, 2020
Celsee, Inc., a leading manufacturer of single-cell analysis equipment, was acquired by Bio-Rad Laboratories, Inc. The acquisition sought to broaden Bio-Rad Laboratories’ product offerings in the single-cell analysis industry.

June 1, 2020
Becton, Dickinson, and Company purchased Straub Medical AG, a leading provider of medical equipment for the diagnosis and treatment of venous disorders. The acquisition sought to broaden Becton, Dickinson and Company’s product portfolio in the vascular access market.

Key Players:

HiMedia Laboratories
F. Hoffmann-La Roche Ltd.
Merck KGaA
Thermo Fisher Scientific
Sartorius AG
S2 Genomics, Inc.
Danaher Corp.
STEMCELL Technologies
BD
Miltenyi Biotec
PAN-Biotech
Key Segments:

Cell Dissociation Industry by Product:

Enzymatic dissociation
Non-enzymatic dissociation
Instruments & Accessories
Cell Dissociation Industry by Type:

Cell dissociation for Tissue Dissociation
Cell dissociation for Cell Detachment
Cell Dissociation Industry by End User:

Cell dissociation for Pharmaceutical and Biotechnology Companies
Cell dissociation for Research and Academic Institutes
Cell Dissociation Industry by Region:

Cell dissociation in North America Market
Cell dissociation in Latin America Market
Cell dissociation in Europe Market
Cell dissociation in East Asia Market
Cell dissociation in South Asia and Pacific Market
Cell dissociation in The Middle East and Africa (MEA) Market

It is anticipated that the small molecule innovator CDMO market will be worth US$ 48.09 billion in 2023 and US$ 89.43 billion in 2033. Sales of small molecule pioneer CDMO are anticipated to increase significantly over the course of the forecast period, at a CAGR of 6.4%.

The small molecule innovator contract development and manufacturing organization (CDMO) market is a rapidly growing and dynamic sector that provides essential services to the pharmaceutical and biotech industries. The market is driven by the increasing demand for outsourcing drug development and manufacturing activities, as well as the growing complexity of drug molecules, which requires specialized expertise and equipment.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16887

The majority of small molecule innovator CDMOs are concentrated in North America and Europe, with a few players in Asia. This is due to the concentration of the pharmaceutical industry in these regions, as well as the regulatory requirements for drug development and manufacturing. The small molecule innovator CDMO market is highly specialized, with players focusing on specific areas such as formulation development, API synthesis, and analytical testing. This allows them to develop deep expertise and offer high-quality services to their clients.

The small molecule innovator CDMO market is adopting new technologies such as continuous manufacturing and automation to increase efficiency and reduce costs. However, the adoption of these technologies is still in its early stages, and many players are still using traditional batch manufacturing methods. Overall, the small molecule innovator CDMO market is a rapidly growing and dynamic sector that provides essential services to the pharmaceutical and biotech industries.

The market is undergoing consolidation, and players are focusing on specialization and technology adoption to stay competitive.

Key Takeaways:

The small molecule API segment is expected to record a swift growth of 6.7% during the forecast period. This expansion can be attributed primarily to regulatory agencies’ high approval rate of NME small molecules.
In 2022, the clinical stage segment held a sub-substantial share of the market, accounting for 55.1% of total revenue. During clinical procedures, CDMOs provide specialized expertise, time savings, and cost efficiency. This is expected to boost segmental growth during the forecast period.
In terms of customer type, pharmaceutical companies had the controllable share (93.9%) in 2022. The growing emphasis on core competencies, such as sales, and the adoption of expansion strategies by CDMOs for manufacturing small molecule drugs, are driving the segment’s market growth.
The oncology segment acquired a prominent share of the market in 2022, accounting for 41.8% of revenue, and it is expected to grow at the fastest rate of more than 7.0% over the forecast period. One of the major factors supporting the segment’s growth is the large number of oncology drugs in the regulatory approval pipeline.
Over the forecast period, Asia Pacific is expected to record a healthy growth of 7.2% because of significantly lower manufacturing costs than in North America and Europe, as well as favorable regulations that encourage innovation
Competitive Landscape:

The presence of numerous competitors in the market influences service pricing, making it a direct source of competition, especially for small-scale providers. To gain a competitive advantage, market vendors are expected to focus on providing one-stop-shop services. With access to significant capital, the CMO could engage in these activities, making entry difficult for new players and increasing competition. Partnerships, company expansions, innovations, and acquisitions are among the strategies used by market participants to improve their product offerings and gain a sustainable competitive advantage.

Latest Developments:

Catalent announced in January 2023 that it had signed a development and license agreement with Ethicann Pharmaceuticals Inc., a Canadian/American specialty pharmaceutical company specializing in developing high-value cannabinoid drug therapies, to advance Ethicann’s clinical drug pipeline using Zydis orally disintegrating tablet (ODT) technology.
Binding Site Group, a global provider of speciality diagnostics, was acquired by Thermo Fisher Scientific Inc. for US$ 2.8 billion in January 2023. The Binding Site expands Thermo Fisher’s already extensive specialized diagnostics range by adding ground-breaking innovation in multiple myeloma diagnosis and monitoring.
Key Companies:

Piramal Pharma Solutions
CordenPharma International
Wuxi AppTec
Cambrex Corporation
Recipharm AB
Pantheon (Thermo Fisher Scientific)
Lonza
Catalent Inc.
Siegfried Holding AG
Boehringer Ingelheim
Labcorp Drug Development
Key Segments:

Product Outlook
Small Molecule API
Small Molecule Drug Product
Oral solid dose
Semi-Solid Dose
Liquid Dose
Others
Stage Type Outlook:

Preclinical
Clinical
Phase I
Small
Medium
Large
Phase II
Small
Medium
Large
Phase III
Small
Medium
Large
Commercial
Customer Type Outlook:

Pharmaceutical
Small
Medium
Large
Biotechnology
Therapeutic Area Outlook:

Cardiovascular disease
Oncology
Respiratory disorders
Neurology
Metabolic disorders
Infectious disease
Others
By Region:

North America
Latin America
Western Europe
Eastern Europe
Asia Pacific Excluding Japan (APEJ)
Japan
Middle East & Africa (MEA)

A recent market research analysis from Future Market Insights projects that, between 2023 and 2033, the global primary hyperoxaluria treatments market will expand at a compound annual growth rate (CAGR) of 8.6%. In terms of value, the market is anticipated to reach more than US$ 41 million by the conclusion of the previously mentioned forecast year.

One of the most promising treatments for primary hyperoxaluria is Lumasiran, a drug that was approved by the U.S. Food and Drug Administration (FDA) in 2020. Lumasiran works by targeting the underlying genetic cause of primary hyperoxaluria, helping to reduce the production of oxalate in the body. Clinical trials of Lumasiran have shown promising results, with patients experiencing significant reductions in urinary oxalate levels and a reduced risk of kidney stone formation.

Unlock valuable insights today. Grab our sample report now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16885

In addition to Lumasiran, there are several other treatments in development for primary hyperoxaluria. These include gene therapy approaches that aim to correct the underlying genetic mutation that causes the condition. There is also ongoing research into the use of existing drugs, such as potassium citrate, in the treatment of primary hyperoxaluria.

The market for primary hyperoxaluria treatment is expected to grow rapidly in the coming years as more therapies become available. This growth is being driven by a number of factors, including increasing awareness and diagnosis of the condition, the development of new treatments, and favorable reimbursement policies. North America is currently the largest market for primary hyperoxaluria treatment, accounting for a significant share of global sales. This is due in part to the high prevalence of primary hyperoxaluria in the region, as well as the strong healthcare infrastructure and favorable reimbursement policies.

Key Takeaways:

From 2018 to 2022, the primary hyperoxaluria treatment market grew at a CAGR of 5.2%.
The global primary hyperoxaluria treatment market is expected to grow with an 8.6% CAGR from 2023 to 2033.
As of 2033, the primary hyperoxaluria treatment market is expected to reach US$ 41.07 million.
According to the FMI analysis, the hospital pharmacies segment accounts for the largest market share.
North America is expected to possess a 40% market share for the Primary Hyperoxaluria Treatment market.
The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering primary hyperoxaluria treatment,” says an FMI analyst

Market Competition

Key players in the market include companies such as Competition Deep Dive, Alnylum Pharma, OxThera, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical Co., Takeda Pharmaceuticals, Wuxi Further Pharmaceutical Co Ltd, Genentech, along with healthcare providers and technology companies among other global players.

In 2020, the United States Food and Drug Administration (FDA) gave the green light to Oxlumo (lumasiran) as the initial treatment for primary hyperoxaluria type 1 (PH1), a rare hereditary disorder. This groundbreaking approval is the culmination of the work of specialists and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
The approval of Oxlumo was a result of input from patients, treating physicians, experts, and sponsors at a patient-focused drug development meeting and through other collaborative efforts. Oxlumo’s function is to reduce the production of oxalate in patients with PH1. The drug was evaluated in two separate trials in PH1 patients: a randomized, placebo-controlled trial in patients aged six years and older, and an open-label study in patients under six years old. The patients ranged in age from four months to 61 years at the start of treatment.
More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global Primary Hyperoxaluria Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of type (type 1, type 2, and type 3), drug class (pyridoxine, potassium citrate, thiazides, and orthophosphates), route of administration (oral and intravenous), and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies) across seven major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa).

Key Segments:

Type:

Type 1
Type 2
Type 3
Drug Class:

Pyridoxine
Potassium Citrate
Thiazides
Orthophosphates
Route of Administration:

Oral
Intravenous
Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

The Latin America Hypodermic Syringes and Needles Market is expected to be worth US$ 207.25 million in 2023 and US$ 360.78 million by 2033. From 2023 to 2033, the market is expected to grow at a 5.9% CAGR.

Increasing incidences of chronic disorder, government initiatives, increasing application of infusion and injection therapies, and the growing demand for injectable vaccines and drugs are some key factors estimated to drive the Latin America hypodermic syringes and needles market.

One of the significant factors bringing lucrative opportunities for market growth is the emerging cases of type one diabetics, which increase the demand for hypodermic syringes and needles.

An increase in surgeries is one of the top factors bolstering the Latin America hypodermic syringes and needles market. According to Worldbank Data, 13,940 surgeries were performed in 2015 in Brazil.

Unlock valuable insights today. Grab our sample report now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16871

Needles usually work through two mechanisms namely safety and non-safety needles. Needles are employed to inject drugs into the body and take fluids from the body for examination.

Huge efforts by the World Health Organization and the United Nations greatly contribute toward increasing consciousness about safe drug delivery practices and decreasing the transmission of diseases is a significant factor projected to impel the growth of the industry.

These organizations have also commenced many initiatives for secure drug delivery. These organizations conducted a few effective programs such as needle & syringe programs; targeted information; education & communication for injecting drug users and their sexual partners; and education & communication for injecting drug users and sexual partners.

Notable Takeaways from Latin America Hypodermic Syringes and Needles Market

In 2022, the syringes segment accounted for the high market share by dominating the market owing to high prices as compared to needles and the rising adoption rate.
Brazil captured a notable market share in 2022 compared to other countries because of the increasing patient pool in the country, and well accessibility of healthcare facilities than the other countries
Venezuela is predicted to record maximum growth in the market owing to the increase in outbreaks of diseases, over the projection period.
The combination segment is the second-leading, in terms of share, in the year 2022 owing to the growing adoption of products to direct insulin.
Competitive Analysis

The competitive landscape Latin America hypodermic syringes and needles industry is marked by several leading players. Notable companies in the market are adopting expansion tactics such as partnerships, mergers, and acquisitions, and launching new products to obtain a competitive edge over other players
Key Development:

Becton, Dickinson, and Company:
A global medical technology company that develops, manufactures, and sells a range of medical devices and diagnostic products, including hypodermic syringes and needles. The company’s products are widely used in healthcare facilities across Latin America.

Covidien Ltd.
A subsidiary of Medtronic, Covidien is a leading provider of healthcare products and services, including hypodermic syringes and needles. The company offers a range of products, including conventional and safety-engineered syringes and needles.

Terumo Corporation:
A global medical device company that develops and manufactures a range of products, including hypodermic syringes and needles. The company’s products are used in a variety of medical settings, including hospitals, clinics, and home healthcare.

Nipro Corporation:
A Japanese company that develops, manufactures, and sells a range of medical devices and equipment, including hypodermic syringes and needles. The company has a significant presence in Latin America and offers a range of products, including conventional and safety-engineered devices.

Market Segmentation

Needles:

16-18G
19-21G
22-25G
26-29G
30-32G
Syringes:

1 to 5 ml
6 to 10 ml
11 to 15 ml
16 to 20 ml
21 to 25 ml
26 to 30 ml
31 to 35 ml
36 to 40 ml
41 to 45 ml
46 to 50 ml
By Region:

Latin America
Mexico
Argentina
Brazil
Chile
Ecuador
Uruguay
Venezuela
Colombia
Bolivia
Peru

The Dental Practise Management Software Market is expected to be worth US$ 2.54 billion in 2023, rising to US$ 6.74 billion by 2033. During the forecast period, sales of dental practise management software are expected to grow at a significant CAGR of 10.25%. Among the factors driving demand for dental practise management software are:

Dental practice management software helps healthcare professionals manage their daily tasks. It helps automate bookkeeping, and inventory management, maximize clinic efficiency, and improve communication between doctors, staff, and patients.

It can be integrated with X-ray sensors, intraoral cameras, imagers, and other dental equipment to keep patient records electronically. Today, dental practice management software runs in the cloud as software as a service (SaaS) or apps, eliminating the need to store patient information on paper and allowing doctors to access data remotely.

Unlock valuable insights today. Grab our sample report now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16864

The growing awareness of oral hygiene has led to an increase in dental examinations worldwide. This is one of the key factors supporting the growth of the market along with the increasing number of the elderly population prone to developing oral diseases and oral diseases.

The ease of paying, booking, and updating information via easy-to-use online portals further fuels the market’s growth. Additionally, integrating IT solutions into oral health services has increased the demand for dental practice management software to reduce clinical errors and improve care delivery.

Cloud-based dental office management software is gaining traction due to its multiple benefits, such as charts and images, claims to track, and automatic claim reminders. The adoption of paperless digital dentistry is gaining ground, which is expected to positively impact market growth in the coming years.

Key Takeaways:

The web-based segment dominated the market with a 55.6% share in 2022. This is due to its low cost, enhanced security, fast updates, and unlimited storage space. Increasing adoption of DPM software in dental practices for billing, reporting, patient records, scheduling, and treatment planning is expected to drive the growth of the segment.
North America leads the overall market with a 40.4% revenue share in 2022. The strategic presence of key players such as Henry Schein One & Curve Dental and baby boomers’ rapid adoption of oral care services is one of the key factors driving United States market growth. Additionally, increased funding for start-ups is likely to support market growth.
The European market is also expected to grow significantly due to rapid technological progress and increased purchasing power. In the 24 months to 30 June 2020, 21 million adults and 6.3 million of their children visited his NHS dentist, according to UK NHS dental statistics.
In 2022, the dental clinic segment was likely to be the market leader, accounting for over 47.4% of total revenue. The industry is growing due to the increasing number of dental offices using dental office management software worldwide.
Manufacturers are constantly expanding their supply chains

The dental laser market’s competitive landscape is moderately fragmented, with a few major companies operating on a global and regional scale. Strategic alliances are being formed by key players in order to expand their respective portfolios and gain a strong foothold in the global market.

Latest Developments

In June 2021, Curve Dental announced an agreement with Dental Intelligence to provide access to Dental Intelligence’s online appointment scheduling system, LocalMed. The purpose of the partnership is to make it easier for dental companies to use Curve Dental’s practice management software, which enables patients to virtually confirm appointments.
Henry Schein announced in May 2021 the development of axiUm Dental Software to integrate dental and medical patient records. New consistency in car modules improves electronic patient file interoperability and information exchange between dentistry and healthcare.
Edge Health Solution Inc. partnered with Allscripts in December 2020 to bring enterprise practice management software to her over 1,000 dentists nationwide to customize patient smiles.
Some of the Key Players Operating in Dental Practice Management Software Market Include:

Henry Schein, Inc.
Carestream Dental, LLC
DentiMax
Practice-Web, Inc.
Nextgen Healthcare, Inc.
ACE Dental Software
Datacon Dental Systems, Inc.
CareStack (Good Methods Global Inc.)
CD Nevco, LLC (Curve Dental)
Dentiflow
Key Segments:

Deployment Mode Outlook:

On-premise
Web-based
Cloud-based
Application Outlook:

Patient Communication
Invoice/Billing
Payment Processing
Insurance Management
Others
End-use Outlook:

Dental Clinics
Hospitals
Others
By Region:

North America
Latin America
Western Europe
Eastern Europe
Asia Pacific excluding Japan (APEJ)
Japan
Middle East & Africa (MEA)

The United States Concierge Medicine Market is expected to be worth US$ 17.97 billion by 2033. Between 2023 and 2033, the concierge medicine industry is expected to grow at a CAGR of 10.32%. Concierge medicine sales in the United States are expected to reach US$ 6.73 billion by 2023.

Same-day appointments, fewer hospitalizations, 24/7 access to medical practitioners, and a focus on primary care are key factors enhancing the United States concierge medicine market growth.

Concierge Medicine is Ideal for Both Patients and Doctors
Both patients and medical professionals win from concierge medicine. As a result, many concierge doctors are converting to this method. The United States has between 10,000 and 25,000 clinicians or subscription-based services, claims Concierge Medical Today, LLC.

Unlock valuable insights today. Grab our sample report now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16860

Several female doctors are converting to concierge practice. Female physicians experience greater stress and burnout. Concierge medicine’s growing popularity is primarily due to physician burnout.
Enhancing patient awareness, improving disposable income, and expanding demand for quality healthcare services are projected to stimulate concierge medicine demand in the United States. Due to these perks, millennials are becoming more interested in concierge practice, strengthening the demand for concierge medicine in the United States.
Hybrid Concierge Approach Resolves Issue of Paucity of Primary Care Physicians

The hybrid concierge approach satisfactorily addresses primary care physician shortages. In the hybrid model, the primary care physician offers patients the option to select either subscription-based treatment or conventional care covered by insurance.

Access to healthcare may be challenging due to the physician shortage,
leading many patients to concierge physicians for more accessible care. Even in a physician shortage, the subscription-based model may guarantee simple access to care. The United States concierge medicine market is believed to be powered by it.

Key Takeaways
• The primary care segment in the specialty category accounts for a considerable United States concierge medicine market share of 25.6% in 2023.
• Physicians downgrade membership-based medicine to reduce stress and improve the overall patient experience. This is likely to amplify specialty category growth in the coming years.
• In 2023, the group sector in the ownership category had 64.1% of the market.
• Doctors combine offices with concierge medical organizations because converting to a retainer model demands legal compliance, advertising, and patient communication. This is positively influencing the ownership segment’s expansion.

Competitive Analysis
With many solo and group concierge physicians, the United States concierge medicine industry is fragmented. Concierge care providers are constantly working to attract famous healthcare professionals to increase membership volume. The leading United States concierge medicine market manufacturers’ common growth strategies are partnership and physician engagement.

Modern Developments
Partnership
Castle Connolly Private Health Partners (CCPHP) and Banner Health announced a partnership to launch the Banner Beyond Program in February 2022. The program offers members a customized and practical experience in a state-of-the-art concierge setting.
Acquisition
Businesses like Crossover Health and Signature MD in the United States concierge medicine industry concentrate on funding and acquisition.
Collaboration

By March 2021, Cypress Membership Medicine and Signature MD announced their planned merger in association with Blue Sea Capital. The merger helped SignatureMD maintain its leading position as a provider of concierge medical services.

Key Players
• MDVIP
• Signature MD
• Crossover Health
• Specialdocs Consultants, LLC
• PartnerMD
• Concierge Consultants & Cardiology
• Castle Connolly Private Health Partners
• Peninsula Doctor
• Cambell Family Medicine
• Destination Health
• Priority Physicians, Inc.
• USA San Diego Health

Key Segments

By Specialty:
• Primary Care
• Pediatrics
• Osteopathy
• Internal Medicine
• Cardiology
• Psychiatry
• Others

By Ownership:
• Standalone
• Group

By Region:
• North America
• Latin America
• Asia Pacific
• Middle East and Africa
• Europe